Antimicrobial Agents and ChemotherapyBiochemistryPeer-reviewed journal article
Cefepime-Taniborbactam and Ceftibuten-Ledaborbactam Maintain Activity Against KPC Variants that Lead to Ceftazidime-Avibactam Resistance
Cullen L. MyersiD, Annie StevensoniD, Brittany Miller, Denis M. DaigleiD, Tsuyoshi UeharaiD, Daniel C. Pevear
Abstract
Klebsiella pneumoniae carbapenemases (KPCs) are widespread {beta}-lactamases that are a major cause of clinical non-susceptibility of Gram-negative bacteria to carbapenems and other {beta}-lactam antibiotics. Ceftazidime combined with the {beta}-lactamase inhibitor avibactam (CAZ-AVI) has been effective for treating infections by KPC-producing bacteria, but emergent KPC variants confer resistance to the combination. Taniborbactam and ledaborbactam are bicyclic boronate {beta}-lactamase inhibitors under development with cefepime and ceftibuten, respectively, to treat carbapenem-resistant bacterial infections. Here, we assessed the effects of clinically important KPC-2 and KPC-3 variants (V240G, D179Y, D179Y T243M) on the antibacterial activity of cefepime-taniborbactam (FEP-TAN) and ceftibuten-ledaborbactam (CTB-LED) and examined catalytic activity and inhibition of these variants. FEP-TAN and CTB-LED were highly active against CAZ-AVI-resistant engineered E. coli strains expressing these variants. Purified KPC variants catalyzed more efficient CAZ hydrolysis than wild-type enzymes, and D179Y-containing KPC-3 variants additionally catalyzed more efficient FEP hydrolysis than wild-type KPC-3. All KPC variants poorly hydrolyzed CTB, and D179Y-containing variants demonstrated significantly higher affinity for CAZ than FEP or CTB. Second-order rate constants (k2/K) for inhibition of D179Y-containing KPC-2 variants were significantly reduced relative to wild-type KPC-2, with AVI most impacted. K2/K was less affected for D179Y-containing KPC-3 variants, and reflected robust inhibition by TAN, LED and AVI. Together, the findings illustrate a biochemical basis for greater FEP-TAN and CTB-LED antibacterial activity in KPC variant expression backgrounds relative to CAZ-AVI, whereby the boronate inhibitors have sufficient inhibitory activity, whilst FEP and CTB are poorer substrates and bind to the variant enzymes with reduced affinity compared to CAZ.
- organism: E. coli
- assay: proteomics
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 13
- FWCI
- 3.33
- Field percentile
- top 7%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Klebsiella pneumoniae mutants resistant to ceftazidime/avibactam plus aztreonam, imipenem/relebactam, meropenem/vaborbactam and cefepime/taniborbactam.
N. Satapoomin, P. Dulyayangkul, M. B. Avison·bioRxiv·Nov 21, 2021
- Emerging Resistance to Novel -βLactam β-Lactamase Inhibitor Combinations in Klebsiella pneumoniae bearing KPC Variants
Mase Hamza, German Matias Traglia, … Maria Soledad Ramirez·Journal of Global Antimicrobial ResistancePeer-reviewed·Jul 15, 2025
- Resistance to Ceftazidime/Avibactam Plus Meropenem/Vaborbactam When Both are Used Together Achieved in Four Steps From Metallo-β-Lactamase Negative Klebsiella pneumoniae.
P. Dulyayangkul, E. Douglas, … M. B. Avison·bioRxiv·Mar 9, 2020
- Exploring mutational possibilities of KPC variants to reach high level resistance to cefiderocol
Sidonie Hanna, Kévin La, … André Birgy·Scientific ReportsPeer-reviewed·Aug 25, 2025
- Genomic and molecular characterisation of a Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam
Yu Wan, Joshua L. C. Wong, … Katie L. Hopkins·bioRxiv·Aug 11, 2025
- The Structural Role of N170 in Substrate-assisted Deacylation in KPC-2 β-Lactamase
D. Parwana, J. Gu, … S. Haider·bioRxiv·May 22, 2023